Does the media prefer LGND or ADMA?

In the previous week, ADMA Biologics had 23 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 32 mentions for ADMA Biologics and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat ADMA Biologics' score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 28 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LGND or ANIP?

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 5 mentions for ANI Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat ANI Pharmaceuticals' score of 0.89 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or UTHR?

In the previous week, United Therapeutics had 12 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 21 mentions for United Therapeutics and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat United Therapeutics' score of 0.68 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INCY or LGND?

In the previous week, Incyte had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for Incyte and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat Incyte's score of 0.79 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NBIX or LGND?

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 5 mentions for Neurocrine Biosciences. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat Neurocrine Biosciences' score of 0.86 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ligand Pharmaceuticals (LGND) Competitors

$314.88 -4.55 (-1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$315.52 +0.63 (+0.20%)

As of 07:57 PM Eastern

Compare

LGND vs. ADMA, ANIP, UTHR, INCY, and NBIX

Should you buy Ligand Pharmaceuticals stock or one of its competitors? MarketBeat compares Ligand Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

In the previous week, ADMA Biologics had 23 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 32 mentions for ADMA Biologics and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat ADMA Biologics' score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	28 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.54	$124.45M	$7.37	42.72
ADMA Biologics	$510.17M	4.16	$146.93M	$0.68	13.47

Ligand Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Ligand Pharmaceuticals currently has a consensus price target of $272.29, suggesting a potential downside of 13.53%. ADMA Biologics has a consensus price target of $19.67, suggesting a potential upside of 114.70%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Ligand Pharmaceuticals has a net margin of 55.95% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
ADMA Biologics	32.43%	39.98%	28.08%

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Ligand Pharmaceuticals presently has a consensus target price of $272.29, indicating a potential downside of 13.53%. ANI Pharmaceuticals has a consensus target price of $107.33, indicating a potential upside of 26.62%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
ANI Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Ligand Pharmaceuticals has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.54	$124.45M	$7.37	42.72
ANI Pharmaceuticals	$883.37M	2.18	$78.34M	$3.95	21.46

Ligand Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 55.95% compared to ANI Pharmaceuticals' net margin of 9.98%. ANI Pharmaceuticals' return on equity of 27.51% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
ANI Pharmaceuticals	9.98%	27.51%	10.02%

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 5 mentions for ANI Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat ANI Pharmaceuticals' score of 0.89 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to United Therapeutics?

Ligand Pharmaceuticals (NASDAQ:LGND) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Ligand Pharmaceuticals has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.54	$124.45M	$7.37	42.72
United Therapeutics	$3.18B	7.39	$1.33B	$27.09	20.46

In the previous week, United Therapeutics had 12 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 21 mentions for United Therapeutics and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat United Therapeutics' score of 0.68 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	12 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals currently has a consensus price target of $272.29, indicating a potential downside of 13.53%. United Therapeutics has a consensus price target of $646.00, indicating a potential upside of 16.53%. Given United Therapeutics' higher possible upside, analysts plainly believe United Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Ligand Pharmaceuticals has a net margin of 55.95% compared to United Therapeutics' net margin of 40.62%. United Therapeutics' return on equity of 19.24% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
United Therapeutics	40.62%	19.24%	17.25%

Summary

United Therapeutics beats Ligand Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

In the previous week, Incyte had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for Incyte and 9 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat Incyte's score of 0.79 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Incyte has higher revenue and earnings than Ligand Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.56	$1.29B	$7.08	16.56
Ligand Pharmaceuticals	$268.09M	23.54	$124.45M	$7.37	42.72

Incyte presently has a consensus target price of $108.20, suggesting a potential downside of 7.73%. Ligand Pharmaceuticals has a consensus target price of $272.29, suggesting a potential downside of 13.53%. Given Incyte's higher probable upside, equities analysts plainly believe Incyte is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

97.0% of Incyte shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Incyte beats Ligand Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Neurocrine Biosciences has higher revenue and earnings than Ligand Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	6.27	$478.60M	$6.49	27.46
Ligand Pharmaceuticals	$268.09M	23.54	$124.45M	$7.37	42.72

In the previous week, Ligand Pharmaceuticals had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 9 mentions for Ligand Pharmaceuticals and 5 mentions for Neurocrine Biosciences. Ligand Pharmaceuticals' average media sentiment score of 1.15 beat Neurocrine Biosciences' score of 0.86 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Neurocrine Biosciences currently has a consensus price target of $188.10, suggesting a potential upside of 5.53%. Ligand Pharmaceuticals has a consensus price target of $272.29, suggesting a potential downside of 13.53%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neurocrine Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Summary

Neurocrine Biosciences beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.40B	$3.80B	$6.99B	$12.46B
Dividend Yield	N/A	2.17%	2.67%	7.39%
P/E Ratio	42.72	21.49	27.17	24.24
Price / Sales	23.54	328.43	534.05	96.53
Price / Cash	40.68	148.60	49.24	56.96
Price / Book	6.09	8.47	10.83	6.38
Net Income	$124.45M	$23.73M	$3.56B	$331.19M
7 Day Performance	0.92%	1.50%	0.81%	-1.84%
1 Month Performance	32.44%	12.00%	5.61%	0.85%
1 Year Performance	173.52%	62.03%	32.58%	22.18%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	2.6235 of 5 stars	$314.88 -1.4%	$272.29 -13.5%	+180.8%	$6.40B	$268.09M	42.72	80	Positive News Analyst Forecast Insider Trade
ADMA ADMA Biologics	4.5241 of 5 stars	$8.95 flat	$19.67 +119.7%	-48.5%	$2.07B	$510.17M	13.16	530	Trending News Analyst Upgrade
ANIP ANI Pharmaceuticals	4.08 of 5 stars	$86.03 flat	$107.33 +24.8%	+32.5%	$1.96B	$883.37M	21.78	600	Insider Trade
UTHR United Therapeutics	4.6961 of 5 stars	$555.91 flat	$619.42 +11.4%	+94.1%	$23.60B	$3.18B	20.52	1,400	Analyst Forecast Insider Trade
INCY Incyte	3.7503 of 5 stars	$116.86 flat	$107.85 -7.7%	+75.5%	$23.35B	$5.14B	16.51	2,844	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, UTHR, INCY, and NBIX

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Summary

How does Ligand Pharmaceuticals compare to Incyte?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, UTHR, INCY, and NBIX

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Does the media prefer LGND or ADMA?

Do institutionals and insiders hold more shares of LGND or ADMA?

Which has stronger earnings and valuation, LGND or ADMA?

Which has more risk & volatility, LGND or ADMA?

Do analysts rate LGND or ADMA?

Is LGND or ADMA more profitable?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Do analysts prefer LGND or ANIP?

Which has higher earnings & valuation, LGND or ANIP?

Which has more volatility & risk, LGND or ANIP?

Is LGND or ANIP more profitable?

Does the media refer more to LGND or ANIP?

Do institutionals and insiders believe in LGND or ANIP?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Which has more volatility and risk, LGND or UTHR?

Do institutionals & insiders believe in LGND or UTHR?

Which has preferable earnings and valuation, LGND or UTHR?

Does the media prefer LGND or UTHR?

Do analysts rate LGND or UTHR?

Is LGND or UTHR more profitable?

Summary

How does Ligand Pharmaceuticals compare to Incyte?

Which has more risk & volatility, INCY or LGND?

Does the media favor INCY or LGND?

Is INCY or LGND more profitable?

Which has preferable valuation & earnings, INCY or LGND?

Do analysts recommend INCY or LGND?

Do institutionals & insiders hold more shares of INCY or LGND?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Which has stronger earnings and valuation, NBIX or LGND?

Does the media favor NBIX or LGND?

Is NBIX or LGND more profitable?

Do analysts prefer NBIX or LGND?

Do insiders & institutionals hold more shares of NBIX or LGND?

Which has more volatility & risk, NBIX or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools